Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of KRAS and BRAF mutations on treatment efficacy and survival in high-grade gastroenteropancreatic neuroendocrine neoplasms.

Journal of neuroendocrinology - 1 Apr 2023

Elvebakken Hege, Hjortland Geir Olav, Garresori Herish, Andresen Per Arne, Janssen Emiel A M, Vintermyr Olav Karsten, Lothe Inger M B, Sorbye Halfdan

Abstract excerpt

High-grade gastroenteropancreatic neuroendocrine neoplasms (HG GEP-NEN) typically disseminate early. Treatment of metastatic disease has limited benefit and prognosis is generally discouraging. Data on the clinical impact of mutations in HG GEP-NEN are scarce. There is an unmet need for reliable biomarkers to predict treatment outcome and prognosis in metastatic HG GEP-NEN. Patients with metastatic HG GEP-NEN...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Neuroendocrine
Share to Disease Progression

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neuroendocrine Tumors

Share to Pancreatic Neoplasms

Share to Prognosis

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins p21(ras)

Share to Treatment Outcome

Source

Identifiers

PMID: 37017614
DOI: 10.1111/jne.13256

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of KRAS and BRAF mutations on treatment efficacy and survival in high-grade gastroenteropancreatic neuroendocrine neoplasms.PMID 37017614Read ↗

Treatment outcome according to genetic tumour alterations and clinical characteristics in digestive high-grade neuroendocrine neoplasms.Semantic proximity Read ↗

BRAFV600E mutation: A promising target in colorectal neuroendocrine carcinoma.Semantic proximity Read ↗

Unraveling molecular pathways of poorly differentiated neuroendocrine carcinomas of the gastroenteropancreatic system: A systematic review.Semantic proximity Read ↗

Genetic Characteristics of Colorectal Neuroendocrine Carcinoma: More Similar to Colorectal Adenocarcinoma.Semantic proximity Read ↗

Molecular profiling of neuroendocrine malignancies to identify prognostic and therapeutic markers: a Fox Chase Cancer Center Pilot StudySemantic proximity Read ↗

Molecular-clinical characteristics and treatment outcomes in 163 metastatic colorectal neuroendocrine carcinomas with a comparison to colorectal adenocarcinomas.Semantic proximity Read ↗

Genetics-guided therapy in neuroendocrine carcinoma: response to BRAF- and MEK-inhibitors.Semantic proximity Read ↗

Prognostic and therapeutic roles of specific genotypes through target-gene sequencing on gastroenteropancreatic neuroendocrine carcinoma.Semantic proximity Read ↗

Comprehensive analysis of mutational and clinicopathologic characteristics of poorly differentiated colorectal neuroendocrine carcinomas.Semantic proximity Read ↗

Mutation Spectrum in Liquid Versus Solid Biopsies From Patients With Advanced Gastroenteropancreatic Neuroendocrine Carcinoma.Semantic proximity Read ↗

Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors.Semantic proximity Read ↗

Novel preclinical gastroenteropancreatic neuroendocrine neoplasia models demonstrate the feasibility of mutation-based targeted therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.